Last reviewed · How we verify
VELCADE Administered by subcutaneous injection
VELCADE is a proteasome inhibitor that blocks the action of proteasomes in cells, leading to cell death.
VELCADE is a proteasome inhibitor that blocks the action of proteasomes in cells, leading to cell death. Used for Multiple myeloma, Mantle cell lymphoma.
At a glance
| Generic name | VELCADE Administered by subcutaneous injection |
|---|---|
| Sponsor | Millennium Pharmaceuticals, Inc. |
| Drug class | Proteasome inhibitor |
| Target | Proteasome |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
VELCADE works by binding to the proteasome, a complex of proteins that breaks down damaged or unneeded proteins in cells. By inhibiting the proteasome, VELCADE prevents the breakdown of proteins that are involved in cell growth and survival, ultimately leading to cell death.
Approved indications
- Multiple myeloma
- Mantle cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Diarrhea
- Nausea
- Vomiting
- Pyrexia
- Headache
- Dizziness
Key clinical trials
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma (PHASE1, PHASE2)
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (PHASE3)
- Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma (PHASE2)
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments (PHASE1)
- A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy (PHASE3)
- GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (PHASE2)
- STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: